Estrogens, Conjugated Tablet, Film Coated
Product Images NDC 50742-391

This text is about a medication called Conjugated Estrogens Tablets, USP, with a dosage of 0.9 mg per tablet. The prescription is for 100 tablets. It includes storage instructions, usual dosage guidance, and a warning to keep the medication out of reach of children. Further details such as expiration date and product identifiers are also provided.*

This is a description of Conjugated Estrogens Tablets, USP, available in a pack of 100 tablets. The medication is only available with a prescription and should be stored in child-resistant containers between 20-25°C (68-77°F) with excursions permitted between 15-30°C (59-86°F). The text mentions the natural occurrence of this medicine and advises to include information for the patient leaflet with each prescription. It emphasizes keeping all medications, including this one, out of the reach of children. The lot number, expiration date, GTIN, and serial number are also provided for reference. The usual dosage instructions are not included in this text.*

This is a description of a tablet that comes in two different strengths: 0.9mg and 125mg. The tablet color may vary depending on the strength, with the 0.9mg tablet containing DAC Yellow# 10 Aluminum Lake and FD&C Yellow #6 Aluminum Lake.*

This text describes Conjugated Estrogens tablets, USP, available in two strengths: 0.9mg (oval, biconvex, white) and 1.25mg (oval, biconvex, yellow). The tablets are debossed with "CT4" and "NL" for the 0.9mg strength, and "CT5" and "NL" for the 1.25mg strength.*

This is a summary tabulation presenting the mean values and comparisons of the number of hot flushes per day for different treatment groups compared to a placebo. The study focuses on patients experiencing at least 7 moderate to severe flushes per day or at least 50 per week at baseline, using the Last Observation Carried Forward (LOCF) method. The table includes data on the number of patients in each treatment group, the baseline mean, observed mean, mean change, and p-values compared to placebo across different time periods. The treatments evaluated are 0.625 mg CE (27 patients), 0.45 mg CE (32 patients), 0.3 mg CE (30 patients), and a Placebo group (26 patients). The analysis was conducted using an analysis of covariance with treatment as a factor and baseline as a covariate.*

This text seems to be presenting a comparison of percent changes in bone mineral density between active treatment and placebo groups in a study. The data includes different regions evaluated such as total body, femoral neck, and femoral trochanter bone mineral density. Baseline measurements, p-values, mean values, and standard deviations for each region are provided for both treatment groups. The study appears to focus on the effect of conjugated estrogens tablets on bone mineral density.*

Table 5 provides a comprehensive overview of the relative and absolute risk observed in the Estrogen Alone Substudy of the Women's Health Initiative (WHI). The data includes information on various health events such as coronary heart disease (CHD) events, non-fatal myocardial infarction (MI), CHD death, strokes (both ischemic and all stroke types), deep vein thrombosis, pulmonary embolism, invasive breast cancer, colorectal cancer, hip fracture, vertebral fractures, lower arm/wrist fractures, total fractures, death due to other causes, and overall mortality. The results are based on centrally adjudicated data with an average follow-up of around 7.1 years. The text also mentions that the results are derived from multiple WHI publications which can be accessed on a specific website. Additionally, it highlights the concept of a "global index" that combines specific events to provide a comprehensive assessment of health outcomes.*

The text provides details on the relative and absolute risk seen in the Estrogen Plus Progestin Substudy of the Women's Health Initiative (WHI) over an average of 5.6 years. The table includes event data such as CHD events, total fractures, invasive breast cancer, and more. The results are derived from WHI publications and are based on centrally adjudicated data. The information includes relative risk comparisons between women taking estrogen plus progestin and those on a placebo. Non-English characters prevent further analysis.*

The text provides information on the relative percentage of subjects, cumulative percentages, percent change from baseline in spine bone mineral density (BMD), and mentions placebo. It appears to be a section of a study or report analyzing bone health data.*